Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 15/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.77 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.77 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.77 |
| ▸ | BLM | P54132 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1322160 | 1.00 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL20579724 | 1.00 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL4351105 | 0.88 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL290702 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL7617534 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL1321676 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| Nitrobenzylmercaptopurine Ribonucleoside SCHEMBL29374837 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL31462888 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL6761745 | 0.87 | SLC29A1 (1.00) | SLC29A1CYP3A4LMNARAB9APKM | |
| SCHEMBL20769890 | 0.83 | SLC29A1 (0.71) | SLC29A1CYP3A4LMNARAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115003669-B | Compounds and their use for the treatment of alpha1Use of antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-115003381-B | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-115003658-B | Compounds and their use for the treatment of alpha1Use of antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-07-23 | — | — | CN | disclosed |
| CN-115023416-B | 4- ((2-oxopyridin-1 (2H) -yl) methyl) benzamide for the treatment of alpha 1-antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-115003380-B | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | 森特萨制药(英国)有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117794538-A | For the treatment of alpha 1 Composition for anti-trypsin deficiency and use thereof | 森特萨制药(英国)有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4073040-A1 | 4-((2-OXOPYRI DIN-1 (2H)-YL)METHYL)BENZAMIDES FOR TREATING ALPHA1 -ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
| EP-4072675-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
| EP-4073043-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF ALPHA1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
| EP-4073068-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
| EP-4072671-A1 | COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY | Z Factor Limited (GB) | 2022-10-19 | — | — | EP | disclosed |
| CN-115023416-A | 4- ((2-oxopyridin-1 (2H) -yl) methyl) benzamides for the treatment of alpha 1-antitrypsin deficiency | Z因子有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-115003669-A | Compounds and their use in the treatment of alpha 1 Use against trypsin deficiency | Z因子有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-115003381-A | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | Z因子有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-115003380-A | Compounds and their use for the treatment of alpha 1-antitrypsin deficiency | Z因子有限公司 | 2022-09-02 | — | — | CN | disclosed |